Source: Eur Respir J 2008; 31: 36-42



Rating:

Share or cite this content

Citations should be made in the following way:
Latzin P., Hartl D., Regamey N., Frey U., Schoeni M. H., Casaulta C.. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008; 31: 36-42

Member's Comments

No comment yet.

Related content which might interest you: Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis Source: Eur Respir J 2003 Oct 01;22(4):592-595 Year: 2003 Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2016; 47: 177-185 Year: 2016 Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Elevated CEA levels in sera in patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2011 - Biomarkers of allergic inflammation Year: 2011 Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis Source: Eur Respir J 2003; 21: 582-588 Year: 2003 Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020 Year: 2020 The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 156 Year: 2001 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 1052-1053 Year: 2001 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Annual Congress 2009 - Update on eosinophilic lung diseases Year: 2009 Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 24: 49-56 Year: 2004 TARC indicates ABPA in CF patients Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006 Mechanisms and markers of airway inflammation in cystic fibrosis Source: Eur Respir J 2002; 19: 333-340 Year: 2002